Job Trends
In a competitive job market, how applicants present themselves in interviews is critical. Asking about promotions and expressing dislike for the work they’d be doing are just a few reasons hiring managers don’t extend job offers.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.
Since the acquisition fell apart, Allergan has fallen on some hard times.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
Medtronic’s building permit for the new facility is valued at $900,000, with the listed architect as Thoda & Associates.
A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon.